Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal oxytocin for social cognitive functioning in chronic schizophrenia
ChiCTR2400089996Phase 4Not yet recruiting
- Sponsor
- Huzhou Third People's Hospital
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of oxytocin in schizophrenia (4 arms), sponsored by Huzhou Third People's Hospital. Primary endpoints: Positive and Negative Syndrome Scale (PANSS), Chinese version of Brief Neurocognitive Test Battery and 2 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
oxytocin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2400089996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089996.